<DOC>
	<DOCNO>NCT02287688</DOCNO>
	<brief_summary>This safety surveillance study Novartis quadrivalent meningococcal ACWY conjugate vaccine ( Meningococcal quadrivalent CRM-197 ) among child 2 month 23 month age post-marketing study require United States Food Drug Administration . It observational study child 2-23 month age receive least one dose MenACWY-CRM vaccine Kaiser Permanente Southern California facility ( KPSC ) enrol KPSC health plan member . The objective infant study describe medical event require emergency room visit hospitalization 6 month follow MenACWY-CRM vaccination child 2-23 month age health maintenance organization United States . Outcomes include medical event require emergency room visit hospitalization child 2-23 month age follow dose MenACWY-CRM vaccination . Events history diagnosis prior first dose MenACWY-CRM vaccination exclude pre-existing condition .</brief_summary>
	<brief_title>Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>child 223 month age time MenACWYCRM vaccination hold KPSC membership time MenACWYCRM vaccination vaccinate MenACWYCRM study period KPSC</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>safety Meningococcal quadrivalent CRM-197 conjugate vaccine</keyword>
	<keyword>Children 2-23 month age</keyword>
</DOC>